David J. Baylink
23Patents
7h-index
15Co-inventors
66Inventor score
Filing activity: Sep 25, 1986 → Jan 16, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9850499B2 | Vectors and methods for the efficient generation of integration/transgene-free induced pluripotent stem cells from peripheral blood cells | Chemistry; Metallurgy | 115 | Active |
| US5195940A | Method for increased production of growth factor in living tissue using an applied fluctuating magnetic field | Human Necessities | 23 | Expired |
| US5330410A | Method for increased production of growth factor in living tissue using an applied fluctuating magnetic field | Human Necessities | 19 | Expired |
| US4911931A | Pharmaceutical combination for treatment of bone-wasting diseases | Human Necessities | 18 | Expired |
| US7816140B2 | Composition and methods for osteogenic gene therapy | Chemistry; Metallurgy | 12 | Active |
| US5851907A | Method for removal of binding proteins from ligands | Physics | 11 | Expired |
| US4859467A | Sustained release fluoride composition | Human Necessities | 7 | Expired |
| US5965136A | Bone resorption assay | Emerging Cross-Sectional Technologies | 6 | Expired |
| US5691305A | Bone implant composition comprising a porous matrix, bone growth promoter proteins, and phosphotyrosyl protein phosphatase inhibitor | Human Necessities | 4 | Expired |
| US5071655A | Pharmaceutical combination for treatment of bone-wasting diseases | Human Necessities | 4 | Expired |
| US5753450A | Bone resorption assay | Emerging Cross-Sectional Technologies | 4 | Expired |
| US8647616B2 | Agents and method for treating inflammation-related conditions and diseases | Chemistry; Metallurgy | 2 | Active |
| US8669104B1 | Agents and method for treating inflammation-related conditions and diseases | Chemistry; Metallurgy | 2 | Active |
| US8722399B1 | Agents and method for treating inflammation-related conditions and diseases | Chemistry; Metallurgy | 2 | Active |
| US5039526A | Buccal lozenge for fluoride ion medication | Human Necessities | 1 | Expired |
| US5599679A | Amino procollagen 1(I) peptides | Physics | 1 | Expired |
| US9789162B2 | Systemic and local ex vivo gene therapy of the skeleton | Chemistry; Metallurgy | 1 | Active |
| US9458215B2 | Compositions and methods for osteogenic gene therapy | Chemistry; Metallurgy | 1 | Active |
| US8772571B2 | Compositions and methods for osteogenic gene therapy | Chemistry; Metallurgy | 1 | Active |
| US10577669B2 | Method for utilizing engineered dendritic cells to induce gut-homing regulatory T cells and treat gut inflammation | Human Necessities | 0 | Active |
| US5807822A | Insulin-like growth factor II as a pharmaceutical agent in the treatment of osteopenias | Human Necessities | 0 | Expired |
| US12275961B2 | Method for utilizing engineered dendritic cells to induce gut-homing regulatory T cells and treat gut inflammation | Human Necessities | 0 | Active |
| US5693754A | Inhibitory binding protein for insulin-like growth factors | Human Necessities | 0 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.